ADAP,Adaptimmune Therapeutics plc | Healthcare

Healthcare

ADAP

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Adaptimmune Therapeutics plcADAP

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.

Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Latest News >

Qualcomm Insider Sold Shares Worth $491,349, According to a Recent SEC Filing

Nov 15, 2024

04:18 PM EST, 11/15/2024 (MT Newswires) -- Akash J. Palkhiwala, CFO & COO, on November 14, 2024, sold 3,000 shares in Qualcomm ( QCOM ) for $491,349. Following the Form 4 filing with the SEC, Palkhiwala has control over a total of 51,778 shares of the company, with 51,778 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/804328/000188831624000077/xslF345X05/edgardoc.xml ...

Freedom Holding Insider Sold Shares Worth $890,125, According to a Recent SEC Filing

Nov 15, 2024

04:19 PM EST, 11/15/2024 (MT Newswires) -- Azamat Yerdessov, Freedom Life CEO, on November 13, 2024, sold 7,662 shares in Freedom Holding ( FRHC ) for $890,125. Following the Form 4 filing with the SEC, Yerdessov has control over a total of 98,338 shares of the company, with 98,338 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/924805/000092963824003950/xslF345X05/form4.xml ...

Arcadium Lithium Insider Sold Shares Worth $322,952, According to a Recent SEC Filing

Nov 15, 2024

04:18 PM EST, 11/15/2024 (MT Newswires) -- Barbara A Fochtman, Chief Operations Officer, on November 13, 2024, sold 61,372 shares in Arcadium Lithium ( ARLTF ) for $322,952. Following the Form 4 filing with the SEC, Fochtman has control over a total of 133,627 shares of the company, with 133,627 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1977303/000095010324016357/xslF345X05/dp220737_4-fochtman.xml Price: 5.42, Change: -0.02,...

Calidi Biotherapeutics Closes $7.5 Million Common Stock Offering

Nov 15, 2024

04:16 PM EST, 11/15/2024 (MT Newswires) -- Calidi Biotherapeutics ( CLDI ) said Friday it closed its public offering of about 4.4 million common shares at $1.69 per share for gross proceeds of around $7.5 million. ...